arrow
D

David Qualls

university of california–san francisco
H指数:15
被引数:589

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ALLOGENEIC HCT AS CONSOLIDATION IN B-CELL LYMPHOMAS AFTER EXPOSURE TO BISPECIFIC ANTIBODIES: A GETH-TC STUDY

暴露于双特异性抗体后,同种异体HCT在b细胞淋巴瘤中的巩固作用: 一项geth-tc研究

2026-01-160
OAAI
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
2024-11-141
OAAI
Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

同种异基因造血细胞移植巩固治疗与无巩固治疗对接受双特异性抗体治疗的非霍奇金淋巴瘤患者的影响

BLOOD
IF23.1
2024-11-050
PRE
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

I期/II期研究中Acalabrutinib、Venetoclax和Obinutuzumab在复发/难治性及初治套细胞淋巴瘤患者中的初步疗效与安全性(MAVO)

BLOOD
IF23.1
2024-11-050
PRE
Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

双难治性(DR)或双暴露(DE) CLL患者的特征与结局

BLOOD
IF23.1
2024-11-050
PRE
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI